Aurora Cannabis Dominates 30% Of Canada's Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?
Aurora Cannabis Dominates 30% Of Canada's Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?
Aurora Cannabis (NASDAQ:ACB) saw its international sales for the first half of 2024 reach C$39.3 million ($28.9 million), reflecting a 31% year-over-year increase. This growth includes the full acquisition of MedReleaf Australia in February 2024, which contributed significantly to the sales boost. A Wednesday report by Pablo Zuanic of Zuanic & Associates provides a detailed analysis of the company's recent activities and financial standing.
極光大麻（NASDAQ:ACB）看到其2024年上半年國際銷售達到C$3930萬（$2890萬），同比增長31%。本次增長包括對澳大利亞MedReleaf的完全收購，該收購對銷售增長做出了重大貢獻。Zuanic & Associates的Pablo Zuanic在週三的一份報告中對公司的最近活動和財務狀況進行了詳細分析。
International Sales And Market Position
國際銷售和市場地位
Aurora remains a leader in the export of Canadian medical marijuana (MMJ), accounting for more than 30% of Canada's MMJ exports.
極光大麻仍然是加拿大醫用大麻出口的領導者，佔加拿大醫用大麻出口量的超過30%。
Key markets include Australia, Germany, Israel, Czechia and Portugal, with notable growth in the Czech and Portuguese markets.
主要市場包括澳大利亞、德國、以色列、捷克和葡萄牙，捷克和葡萄牙市場增長明顯。
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
獲取Benzinga獨家分析以及關於大麻行業和市場的最新資訊，每天免費發送到您的郵箱。點擊此處訂閱我們的新聞稿。如果您認真對待業務，那麼不能錯過。
Profit Margins And Cash Flow Trends
利潤率和現金流趨勢
The company reported encouraging profit margin trends, with adjusted cash gross margins for its global cannabis business reaching 69% in the June quarter, up from 66% in March and 61% a year ago.
公司報告顯示，2024年6月季度全球大麻業務的調整後現金毛利率達到69%，高於3月的66%和一年前的61%。
Despite this, recurring cash operating expenses in Q2 2024 were slightly higher than adjusted cash gross profits, leading to a 102% ratio.
儘管如此，2024年Q2的經常性現金營業費用略高於調整後現金毛利潤，比例達到102%。
Still, this represents an improvement compared to the previous fiscal year. Aurora's net cash position improved to C$63 million, with positive operating cash flows of C$8.4 million for the quarter.
不過，與上個財年相比，這表示了一種改善。極光大麻的淨現金狀況改善到6300萬加幣，本季度的營業現金流爲840萬加幣。
Valuation And Strategic Outlook
估值和戰略展望
Aurora Cannabis is currently valued at C$516 million, with an enterprise value of C$543 million. The company trades at 1.6 times its current sales run rate, significantly below the multiples seen by competitors like Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC). Zuanic suggests that while Aurora's financial and operational trends are showing signs of improvement, the company's valuation remains relatively attractive compared to its peers.
極光大麻目前的估值爲51600萬加幣，企業價值爲54300萬加幣。公司的交易價格是其當前銷售速率的1.6倍，遠低於競爭對手如Tilray（納斯達克：TLRY）和Canopy Growth（納斯達克：CGC）的倍數。Zuanic認爲，儘管極光大麻的財務和運營趨勢顯示出改善跡象，但與同行相比，公司的估值仍然相對較有吸引力。
Cover image made with AI
封面圖片由人工智能製作
譯文內容由第三人軟體翻譯。
